Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 5Phase 1/2 2Phase 4 1Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 3Lymphoma 3Hodgkin Disease 3Lymphoma, T-Cell 2Hematologic Diseases 2Neoplasms by Histologic Type 1Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphatic Diseases 1Immunoproliferative Disorders 1Immune System Diseases 1

Interventions

Rituximab 5Cyclophosphamide 3pirtobrutinib 2pegfilgrastim 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Drug Therapy 2Doxorubicin 2temsirolimus 1plerixafor 1pegylated granulocyte colony-stimulating factor 1ledipasvir, sofosbuvir drug combination 1ibrutinib 1ibritumomab tiuxetan 1fludarabine phosphate 1entecavir 1Vincristine 1Valsartan 1Thiotepa 1Tenofovir 1Sofosbuvir 1Ribavirin 1Radiotherapy 1Prilocaine 1Prednisone 1Oxygen 1Ifosfamide 1Fibroblast Growth Factor 7 1Dexamethasone 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Lymphoma, Non-Hodgkin × Brentuximab Vedotin × Clear all
NCT01909934 2025-09-19

Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Takeda

Phase 4 Completed
50 enrolled 22 charts
Lymphoid

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡